A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Patrick J GroharJohn W GlodCody J PeerTristan M SissungFernanda I ArnaldezLauren LongWilliam D FiggPatricia WhitcombLee J HelmanBrigitte C Widemann

Published in: Cancer chemotherapy and pharmacology (2017)

Hepatotoxicity precluded the administration of a mithramycin at a dose required to inhibit EWS-FLI1. Evaluation of mithramycin in patients selected for decreased susceptibility to elevated transaminases may allow for improved drug exposure.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
young adults
clinical trial
prognostic factors
emergency department
rna seq
patient reported outcomes
single cell
electronic health record